Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha therapies (TATs) for cancer treatment using Lead-212 (212Pb), an alpha-emitting radioactive isotope attached to a targeting peptide that binds to receptors overexpressed on cancer cells. Alpha particles travel only one to two cell lengths, so the approach delivers lethal radiation directly to tumors while minimizing damage to surrounding tissue. A key differentiator is Perspective's theranostic approach: the company first images tumors using Lead-203, a chemically identical isotope that emits gamma rays, allowing clinicians to predict how therapy will distribute in a given patient and select only those likely to respond. Perspective has three lead clinical programs: VMT-α-NET for neuroendocrine tumors (the most advanced, with an early 39% objective response rate in one cohort and a strategic option agreement with Lantheus), VMT01 for melanoma, and PSV359 targeting a broad pan-cancer marker. The company is pre-revenue and funds operations through equity offerings. If products are approved, Perspective would sell to hospitals and cancer centers, with revenue driven by patients treated and reimbursement rates. A defining operational feature is manufacturing: because 212Pb has a half-life of only 10.6 hours, finished drug must be produced near patients, so Perspective is building a distributed regional network of production facilities across the U.S. Perspective also controls its own 212Pb supply through proprietary generator technology, sourcing the Thorium-228 feedstock primarily from the U.S. Department of Energy.